Credit Suisse analyst Martin Auster upgraded Esperion Therapeutics (NASDAQ: ESPR) from Neutral to Outperform with a price target of $45.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE